Pancreatic polypeptide (PP) and peptide YY (PYY) are released by the gut in response to nutrients and inhibit food intake in rodents and humans. We hypothesized that PP and PYY 3À36 would inhibit feeding additively. Fasted male C57BL/6 mice were injected intraperitoneally with saline, PP, PYY 3À36 or PP þ PYY 3À36 (n ¼ 7-10). Food intake at 1 h was significantly inhibited by 6 nmol kg À1 PP and by 6 nmol kg À1 PYY 3-36 (Po0.05) but not significantly following 3 nmol kg À1 PP þ 3 nmol kg À1 PYY 3À36 . In a higher dose study 30 nmol kg À1 PP, 30 nmol kg À1 PYY 3À36 and 30 nmol kg À1 PP þ 30 nmol kg À1 PYY 3À36 all inhibited 1 h food intake compared with saline (Po0.05) but there was no significant difference in the food intake of the combined group compared with either hormone individually. Subsequently, 16 fasted lean healthy human volunteers (6 men and 10 women) received, in random order, 90 min intravenous infusions of saline, 4 pmol kg À1 min À1 PP, 0.4 pmol kg À1 min À1 PYY 3À36 and 4 pmol kg À1 min À1 PP þ 0.4 pmol kg À1 min À1 PYY 3À36 . A pasta lunch was served 60 min following infusion. There was no evidence of a greater decrease in food intake with the combined PP þ PYY 3À36 treatment (buffet meal energy intake (KJ): saline 2633 ± 204, PP þ PYY 2693 ± 254, PP 2367 ± 199, PYY 2511 ± 196). These results suggest that PP and PYY 3À36 do not inhibit feeding additively in rodents or humans.
Introduction
Pancreatic polypeptide (PP) and peptide YY (PYY) are members of the neuropeptide Y (NPY) family, which have been reported to inhibit feeding individually in rodents and humans. [1] [2] [3] In response to food, PP is secreted from the pancreatic islets of Langerhans 4 and PYY 1À36 is secreted from the endocrine L-cells of the small and large bowel 5 and truncated to PYY 3À36 in the plasma by the enzyme DPP-IV. 6 Both peptides are thought to bind to the hypothalamic Y-family receptors. PP binds primarily to the Y4 receptor 7 and PYY 3À36 binds predominantly to the Y2 receptor. 8 In addition to their central actions, PP and PYY may also inhibit food intake through a reduction in gut motility. 9, 10 There is evidence that co-administration of appetiterelated peptides may inhibit feeding synergistically. The gut hormone cholecystokinin-8 (CCK-8) potentiated the appetite inhibitory effects of the adipocyte hormone, leptin, in rodents. 11 More recently, the gut hormones, PYY 3À36 and GLP-1 7À36 , were reported to inhibit feeding additively in rodents and humans at low doses at which neither peptide significantly altered feeding when administered individually. 12 Low-dose combined peptide administration could have the therapeutic advantage of greater inhibition of feeding with a more favourable side-effect profile. In the current investigation we hypothesized that PP and PYY 3À36 would also inhibit feeding additively in rodents and humans.
Methods
Synthetic human PP and PYY 3À36 were purchased from Bachem (Merseyside, UK). All animal procedures were approved by the British Home Office Animals (Scientific Procedures) Act 1986 (Project License number 70/5281). Male C57BL/6 wild-type mice were purchased from Charles River Laboratories UK (Margate, Kent, UK) and were maintained in individual cages and handled as previously described. 12 Mice aged 8-9 weeks and weighing 20-25 g were fasted from 1500 hours until the following morning when they received an intraperitoneal (IP) injection (volume 0.1 ml) at 0900 hours. In the low-dose study, mice received saline, 3 PYY 3À36 (n ¼ 10) . These doses were chosen from previously published studies. 1, 12 Following injection all mice were presented with a pre-weighed quantity of chow. The remaining food was measured at 1, 2, 4, 8 and 24 h following injection and food intake calculated. The human study was approved by the Riverside Research Ethics Committee and run according to the principles of the Declaration of Helsinki. Sixteen healthy lean volunteers (6 men and 10 women) were recruited to the study of age 28.6 ± 1.6 years and BMI 22.4 ± 0.5 kg/m 2 as previously described. 13 All volunteers gave written informed consent and were instructed to fast from 2100 hours on the evening before infusions. Volunteers attended for four 90 min intravenous infusions starting at 0930 hours in randomised order (saline, 4 pmol kg
PYY 3À36 and 4 pmol kg
PYY 3À36 ) at least 72 h apart. At 1200 hours, (60 min after the end of the infusion) a buffet pasta lunch was served and food intake calculated. The PP dose was chosen just below the minimum dose of PP, which has been reported to inhibit energy intake in humans.
14 The PYY 3À36 dose was selected at a dose that inhibited feeding additively with GLP-1 7À36 in humans. 12 Previous studies in rodents and humans suggest that PP is approximately equipotent with PYY in mice whereas PP is less potent than PYY in humans. 1, 12, 14 This might be explained by inter-species variation.
For the rodent studies data were analysed using a one-way analysis of variance (ANOVA) with a Dunnett's 2-sided post hoc test. In the human study, percentage energy intakes of an individual's saline day were analysed using a one-way repeated-measures ANOVA and within-subject effect examined with a Fischer least significant difference test.
Results
In the low-dose rodent study, food intake at 1 h was significantly inhibited by 6 nmol kg À1 PP and by 6 nmol kg À1 PYY 3À36 . However, no significant inhibition of food intake was seen following the combined treatment (3 nmol kg (Figure 1 ). At these low doses there were no significant differences in cumulative food intake at 4 h or at subsequent time points between treatment groups. In the high-dose study, 30 nmol/ kg À1 PP, 30 nmol kg À1 PYY 3À36 and 30 nmol kg À1 PP þ 30 nmol kg À1 PYY 3À36 all inhibited 1 h food intake compared with saline (Po0.05) but there was no significant difference in the food intake of the combined group compared with either hormone individually (food intake 0-1 h (g): saline 1.18 ± 0.05, PP 0.74 ± 0.08, PYY 0.76 ± 0.03, PP þ PYY 0.68 ± 0.08). There were no significant differences in cumulative food intake between the combined group and the individual peptides at subsequent time points. In the human study, no adverse effects were observed or reported on any infusion day. At these low doses, although there was a trend for PP to inhibit buffet meal energy intake (P ¼ 0.09), neither PP nor PYY 3À36 significantly inhibited energy intake consistent with previously published studies. 12, 14, 15 There was no evidence of an additive inhibitory feeding effect with the combined PP þ PYY 3À36 treatment (buffet meal energy intake (KJ): saline 2633±204, PP þ PYY 2693 ± 254, PP 2367 ± 199, PYY 2511 ± 196) ( Figure 2 ). In fact, the energy intake on the PP þ PYY infusion day was significantly more than on the PP infusion day alone (P ¼ 0.04).
Discussion
These rodent and human data suggest that PP and PYY 3À36 do not inhibit feeding additively. This was unexpected, given Effect of PP and PYY 3À36 on feeding NM Neary et al that both peptides are thought to act primarily through different receptors. In addition to their respective binding to the Y4 and Y2 receptors, human PP and PYY 3À36 have significant binding affinity for the appetite-stimulatory Y5 receptor. 10, 16 Theoretically, Y5 receptor stimulation could act to oppose the appetite inhibition associated with the Y2 and Y4 receptors. In the human study, energy intake was statistically greater following the combined PP þ PYY infusion compared with PP infusion alone. This raises the possibility that the addition of PYY 3À36 to PP might oppose the inhibitory feeding effect of PP alone. In contrast, in the rodent studies there was a small but not statistically significant decrease in food intake with the combined treatment compared with either peptide alone. It is possible that the intravenous PP and PYY 3À36 administration route of the human study led to more rapid hypothalamic receptor activation than the IP route of the rodent studies, which could favour relatively more Y5 receptor activation. However, we cannot exclude the possibility of unknown interactions, which could affect any of the Y receptor system. It seems that peptides from discrete families, which act through entirely independent receptor systems, are more likely to inhibit feeding additively. For example, pairs of appetite inhibitory hormones that have been reported to inhibit feeding additively, such as CCK-8 and leptin, 11 PYY 3À36 and GLP-1 7À36 , 12 and PYY 3À36 and exendin-4, 17 consist of two peptides from different families. From a physiological point of view, these results may suggest that the rise in endogenous PP and PYY following a meal may not inhibit feeding additively. However, as PP and PYY both remain elevated for approximately 6 h following a meal they have different release profiles. Circulating PYY levels rise to a plateau in humans 1-2 h after a meal, 5 whereas post-prandial PP release is biphasic. 18 It is likely that these dynamic changes in PP and PYY levels are associated with a complex combined effect on feeding following meals. From the therapeutic viewpoint this preliminary investigation suggests that there is no advantage in co-administering PP with PYY 3À36. Indeed, the dual infusion seemed less effective than separately. Further study is required to understand this phenomenon.
